As Supplement GMP Implementation Hits Zero Hour, Small Firms Struggle
This article was originally published in The Pink Sheet Daily
Executive Summary
Consultants say GMP warning letters are invaluable tools to study in advance of FDA's GMP inspection, which should begin for dietary supplement manufacturers with fewer than 20 employees late this summer or in the fall.
You may also be interested in...
Atlas widens ED supplement recall
Atlas Operations expands the voluntary recall of its sexual enhancement dietary supplements to include the Stamin It, Erectzia, and Vigor 100 products. The Pompano Beach, Fla.-based firm's initial recall began Dec. 12, 2009, after FDA found its products to contain sulfoaildenafil, an analog of sildenafil - an Rx ingredient for erectile dysfunction (1"The Tan Sheet" Dec. 21, 2009, In Brief). Atlas said April 12 it discovered one of its raw ingredients was tainted with sulfoaildenafil, but maintains it did "not in any way knowingly or intentionally violate the law with regard to the distribution of these products." Sexual enhancement and weight-loss products are the types of supplements that FDA most commonly finds to be adulterated with Rx ingredients, and are frequently mentioned by proponents of tighter regulation of the U.S. nutritional products market
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.